ChemicalBook Product Catalog API Antibiotics Other antibiotic Drugs Arbekacin

1/5

Arbekacin

$ 1.00 /1g

Min. Order1g
Purity≥98%
Cas No51025-85-5
Supply Abilityg/kg/Ton
Update time2019-12-26

career henan chemical co

5YR

China

Chemical Properties

Product Name	Arbekacin
CAS No	51025-85-5
EC-No
Min. Order	1g
Purity	≥98%
Supply Ability	g/kg/Ton
Release date	2019/12/26

Heidi 0656

Email:heidi@coreychem.com

▼

▲

Arbekacin Basic information

▼

▲

Product Name:

Arbekacin

Synonyms:

AHB[1KB;Blubatosine;(s)-oxy-1-oxobutyl)-2-deoxy;Decontasin;4-O-[3-Amino-3-deoxy-α-D-glucopyranosyl]-6-O-[2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl]-N'-[(2S)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy-L-streptamine;6-O-(3-Amino-3-deoxy-α-D-glucopyranosyl)-4-O-(2,6-diamino-2,3,4,6-tetradeoxy-α-D-erythro-hexopyranosyl)-N1-[(S)-4-amino-2-hydroxybutyryl]-2-deoxy-D-streptamine;3,4,6-tetradeoxy-alpha-d-erythro-hexopyranosyl-(1-4))-n(sup1)-(4-amino-2-hydr;habekacin

CAS:

51025-85-5

MF:

C22H44N6O10

MW:

552.62

EINECS:

Product Categories:

Mol File:

51025-85-5.mol

▼

▲

Arbekacin Chemical Properties

▼

▲

Boiling point

904.0±65.0 °C(Predicted)

density

1.47±0.1 g/cm3(Predicted)

pka

13.07±0.70(Predicted)

CAS DataBase Reference

51025-85-5(CAS DataBase Reference)

▼

▲

Safety Information

▼

▲

▼

▲

MSDS Information

▼

▲

Arbekacin Usage And Synthesis

▼

▲

Description

Arbekacin is a semi-synthetic derivative of dibekacin useful in the treatment of bacterial infections. This aminoglycoside is active against a broad spectrum of bacteria, including some of the gentamycin-, kanamycin-, and tobramycin-resistant pathogens. Compared to amikacin and dibekacin, ototoxicity is reportedly milder.

Originator

Inst. Microbial Chemistry (Japan)

Definition

ChEBI: A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring.

Brand name

Habekacin

Antimicrobial activity

The 1-N-(4-amino-2-hydroxybutyryl) derivative of dibekacin, to which it bears the same relation as amikacin bears to kanamycin A. Supplied as the sulfate.
Activity and stability to aminoglycoside-modifying enzymes are comparable with those of amikacin. It is active against many strains of methicillin-resistant Staph. aureus, either alone or in combination with β-lactam or other agents. Synergy with ampicillin has been observed for high-level gentamicin- and vancomycin-resistant enterococci.
A 3 mg/kg intravenous dose achieved a peak concentration of c. 8 mg/L after 1 h. The plasma half-life is about 2 h and protein binding 3–12%.
About 85% of the dose can be recovered from urine over 48 h. It is retained in renal failure, but moderately well removed by hemodialysis with a plasma half-life of 2–4 h. Peak concentrations of 10.9 mg/L and trough concentrations of 1.7 mg/L have been reported in patients treated for MRSA infection where C_max:MIC ratios of >25 and AUC:MIC ratios of >186 were associated with improved cure rates, and both Cmin and AUC were associated with the incidence of nephrotoxicity.
Toxicity and side effects are typical of the aminoglycoside class. It is used in severe infection cause by susceptible microorganisms, but is not widely available.

Company Profile Introduction

Recommended supplier

Send Inquriy

Arbekacin

Company Profile Introduction

You may like

Recommended supplier